BVS news

Latest 2 stories · newest Nov 2, 2026

BVS

Bioventus Q3 Revenue Grows 3%; Cash Flow Healthy

Bioventus reported Q3 revenue of $142.4 million, driven by Pain Treatments, and Non-GAAP earnings of $0.17 per share. The company continues to review strategic alternatives.

Earnings Nov 2, 2026 sentiment +0.30 SEC filing ↗

BVS

Bioventus Q2 revenue increases 4% to $153.2M

Bioventus reported Q2 financial results with revenue and GAAP earnings rising. The company initiated a review of strategic alternatives at a positive momentum point.

Guidance|M&A Aug 5, 2026 sentiment +0.10 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same BVS feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/BVS/newsSTART FREE